University of Hertfordshire

From the same journal

By the same authors

View graph of relations
Original languageEnglish
Number of pages4
Pages (from-to)762-5
JournalJournal of Antimicrobial Chemotherapy
Journal publication date2008
Volume62
Issue4
DOIs
Publication statusPublished - 2008

Abstract

Clostridium difficile infection is a nosocomial disease of increasing importance. First-line treatment is limited to metronidazole or vancomycin. Oritavancin is a lipoglycopeptide with activity against Gram-positive bacteria, including drug-resistant pathogens. MICs of oritavancin, metronidazole and vancomycin for genotypically distinct C. difficile strains, including epidemic C. difficile PCR ribotypes 001 and 027, were determined by agar incorporation and broth macrodilution methods. In agar incorporation methods, the impact of supplements on oritavancin MICs was tested to address oritavancin binding to surfaces.

ID: 1352019